Overview
What is The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc, headquartered in Rye Brook, New York, is a leading nonprofit organization dedicated to advancing research and treatments for blood cancer, including leukemia, lymphoma, Hodgkin's disease, and myeloma. They have been instrumental in funding and accelerating research that has led to the approval of 75% of the nearly 100 new blood cancer treatments over the past five years. Their research efforts span the entire continuum, from basic laboratory science to clinical trials and private-sector drug development alliances. Their mission is to cure blood cancers and improve patients' lives and their families'. They have invested over 1.6 billion dollars in research to date and have seen significant advancements, such as Chimeric Antigen Receptor T cell (CAR T) therapy, which has produced cures for some patients who have exhausted all other options. In fiscal year 2022, they supported research in the US, Canada, and nine other countries with a total research disbursement of approximately 54.6 million dollars. They also introduced Impact Research Grants to address unequal representation of underserved populations in clinical trials, with a goal of increasing trial enrollment among these populations to at least 20%. Additionally, their Therapy Acceleration Program (TAP) has partnered with over 70 biotech companies and academic researchers to extend the therapeutic landscape in blood cancer, leading to three FDA approvals and over 20 active clinical studies.
Official website here: www.lls.org
Is The Leukemia & Lymphoma Societyinc legitimate?
The Leukemia & Lymphoma Societyinc is a legitimate nonprofit organization registered as a 501(c)(3) entity. The Leukemia & Lymphoma Societyinc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $2,091,645
Professional Fundraising Fees: $5,554,287
Other Salaries and Wages: $88,505,319
For more financial information, click here
Official website here: www.lls.org
What is the mission statement of The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc is dedicated to curing leukemia, lymphoma, Hodgkin's disease, and myeloma, and improving the quality of life for patients and their families. They achieve this by funding groundbreaking cancer research and propelling novel treatments through various stages of the drug approval process. Over the last five years, LLS support has contributed to 75% of the almost 100 blood cancer treatment approvals. Their investment in research initiatives, such as precision medicine, immunotherapy, and mutation-linked treatments, is transforming the landscape of cancer care. The society's deliberate and purposeful approach to research has led to the development of lifesaving and less toxic therapies, including CAR T therapy, which has produced cures in patients who have failed all other therapeutic options. The organization's investment in research totals over 1.6 billion dollars and has had significant impact in extending the therapeutic landscape for blood cancer patients. In fiscal year 2022, they supported research in the US, Canada, and 9 other countries. Additionally, LLS has introduced Impact Research Grants to address unequal representation of underserved populations in clinical trials and expand access to state-of-the-art therapies for a broader range of newly diagnosed blood cancer patients.
Official website here: www.lls.org
Who is the CEO of The Leukemia & Lymphoma Societyinc?
Louis J Degennaro is the President & of The Leukemia & Lymphoma Societyinc.
Official website here: www.lls.org
What is the revenue of The Leukemia & Lymphoma Societyinc?
The Leukemia & Lymphoma Societyinc's revenue in 2022 was $426,997,204.
Official website here: www.lls.org
Who are the executives of The Leukemia & Lymphoma Societyinc and what are their salaries?
The average compensation at The Leukemia & Lymphoma Societyinc during 2022 was $76,973. There are 1,177 employees at The Leukemia & Lymphoma Societyinc.
Here are 28 key members and their salaries:
- Louis J Degennaro (President &)
- Gwen Nichols Md (Evp Chief Me)
- Troy Dunmire (Evp Chief Op)
- Gordon Miller Jr (Evp Chief Fi)
- Dale Nissenbaum (Evp Gen Coun)
- Coker Powell (Svp Chief De)
- Tom Osgood (Evp Chief Hr)
- Vanessa White (Svp Chief Ad)
- Lee M Greenberger (Svp Chief Sc)
- Richard Bagger (Bod Member) [Trustee/Director]
- Michele Cameron (Bod Member) [Trustee/Director]
- Ruben Mesa Md Facp (At Large) [Trustee/Director]
- Christopher Flowers (Bod Member) [Trustee/Director]
- John Greene (Bod Member) [Trustee/Director]
- Francie Heller (Bod Member) [Trustee/Director]
- Ralph E Lawson (Bod Member) [Trustee/Director]
- Casey Cunningham Md (Bod Member) [Trustee/Director]
- Janice Gabrilove Md (Bod Member) [Trustee/Director]
- Renzo Canetta Md (Bod Member) [Trustee/Director]
- Kathleen Meriwether (Vice Chair) [Trustee/Director]
- Lynne O'Brien (Bod Member) [Trustee/Director]
- Marla Persky (Bod Member) [Trustee/Director]
- Richard Rendina (Bod Member) [Trustee/Director]
- Robert Rosen (Bod Member) [Trustee/Director]
- Jeff Sachs (Chair) [Trustee/Director]
- Bart Sichel (Bod Member) [Trustee/Director]
- Alessandra Tocco (Bod Member) [Trustee/Director]
- Freda Wang (Secretary/Tr) [Trustee/Director]
Official website here: www.lls.org
Where can I find the form 990 for The Leukemia & Lymphoma Societyinc?
The The Leukemia & Lymphoma Societyinc’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.lls.org
Learn more at the official website: www.lls.org
Mission Statement of The Leukemia & Lymphoma Societyinc
The Leukemia & Lymphoma Societyinc (LLS) is a leading organization in the mission to cure leukemia, lymphoma, Hodgkin's disease, and myeloma, as well as improving the quality of life for patients and their families. LLS's relentless pursuit of advancements in cancer research propels groundbreaking treatments through all phases of the drug approval process. With a significant investment of over 1.6 billion dollars towards research, LLS has been instrumental in the approval of 75% of blood cancer treatments over the last five years.
LLS's impact reaches beyond the United States, with research funding distributed in 9 other countries. The organization's commitment to finding and supporting research most likely to benefit patients as soon as possible is evident in their sustained investments over several decades. One of the most notable successes includes their early investment in Chimeric Antigen Receptor T cell (CAR T) therapy in 1990, which has resulted in 12 FDA-approved CAR T therapies for acute B-cell leukemia, non-Hodgkin lymphoma, and multiple myeloma. These therapies have produced cures for patients who have exhausted all other therapeutic options.
In addition to research, LLS also aims to increase clinical trial enrollment among underrepresented populations. The organization's Impact Research Grants, a five-year investment of 3.75 million dollars, aims to expand clinical trial access to local community-based hospitals and clinics. This initiative will help increase trial enrollment among racial and ethnic minorities, rural residents, and individuals with low income, ensuring that a broader range of newly diagnosed blood cancer patients have access to state-of-the-art therapies.
In summary, The Leukemia & Lymphoma Societyinc is an influential organization dedicated to curing blood cancers and improving patients' lives. With a rich history of groundbreaking research and a commitment to increasing access to clinical trials, LLS is at the forefront of advancing treatments for leukemia, lymphoma, Hodgkin's disease, and myeloma.
Impact
This information is meant to be a general summary of The Leukemia & Lymphoma Societyinc. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
The Leukemia & Lymphoma Societyinc's impact is significant in the field of cancer research and patient care. They have invested over $1.6 billion in research aimed at helping all blood cancer patients live better, longer lives. Their sustained research investment has led to groundbreaking advancements, including the development of Chimeric Antigen Receptor T Cell (CAR T) therapy, which has resulted in 12 FDA-approved therapies for various blood cancers.
The organization's Therapy Acceleration Program (TAP) has partnered with over 70 biotechnology companies and academic researchers, investing over $130 million and leading to 3 FDA approvals. They actively support clinical studies with the potential for new FDA approvals in the near future, contributing to advancements in leukemia, lymphoma, and multiple myeloma treatments.
Furthermore, The Leukemia & Lymphoma Societyinc has facilitated collaborations with medical institutions and organizations to conduct innovative clinical trials like the BEAT AML Master Trial and the Pediatric Acute Leukemia (PEDAL) Master Trial. These trials focus on testing novel targeted therapies and bringing precision medicine to the treatment of blood cancers, ultimately improving outcomes for patients.
In addition to their research efforts, the organization established the LLS National Patient Registry to address the impact of the COVID-19 pandemic on the blood cancer community. Through this initiative, they have collected valuable data on vaccine safety and efficacy for blood cancer patients, aiding healthcare providers and public health officials in making informed decisions.
Overall, The Leukemia & Lymphoma Societyinc's commitment to advancing research, developing innovative therapies, and supporting patient care initiatives has had a profound impact on the fight against blood cancers, driving progress towards finding cures and improving the quality of life for patients and their families.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
SERVICE REVENUE
Revenue
$11,597,762
Organization Details
Founding Year
1949
Phone
(914) 949-5213
Principal Officer
Louis J Degennaro
Main Address
3 INTERNATIONAL DRIVE SUITE 200, RYE BROOK, NY, 10573
Website
www.lls.org
NTEE Category
Code: G30 - Disease
If you are a representative of The Leukemia & Lymphoma Societyinc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.